US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AdvisorShares Psychedelics ETF

24.50

-0.6200-2.47%

Post-market: 25.521.02+4.16%19:30 EDT

Volume:57.51K

Turnover:1.41M

Market Cap:56.84M

PE:- -

High:25.32

Open:25.24

Low:24.14

Close:25.12

52wk High:27.02

52wk Low:15.63

Shares:2.32M

Float Shares:2.32M

Volume Ratio:1.27

T/O Rate:2.48%

Dividend:1.70

Dividend Rate:6.95%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Vanadium Resources Plans Major Share and Option Placement on ASX

Psychedelic: Optimi to initiate Phase 2 trial of psilocybin-assisted therapy

Optimi Health to initiate Phase 2 trial of psilocybin-assisted therapy for MDD

Alkermes Announces Launch of 9TH Annual Alkermes Pathways Research Awards® Program

THOMSON REUTERS

Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval Comp360 Provider Training

THOMSON REUTERS

Compass Pathways Management Attends Investor Conference Fireside Chats in New York Week of Sept. 14

Disc Medicine presents initial results from RESTORE phase 2 trial in PV patients

U.S. Stocks on the MOVE-UGI, Chewy, Cognyte Software

Compass Pathways Rises After One-Year Data for Psychedelic-Based Depression Drug

Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 Comp005 Trial Demonstrates Additional Benefit from Another Comp360 Dose in Part C Extending Durability Out to 1 Year

THOMSON REUTERS

Compass Pathways - Rolling Nda Submission Underway; Final Submission on Track for Q4

THOMSON REUTERS

Compass Pathways - Continue to Expect Commercial Launch in H1 2027

THOMSON REUTERS

Compass Pathways - Comp360 Safety Profile in Part C Consistent with Prior Parts; no New Safety Findings

THOMSON REUTERS

Compass Pathways - 25 Mg Arm Shows Average 13-Point Madrs Reduction at Week 52 with Durability to 1 Year

THOMSON REUTERS

Aureka launches placement and share purchase plan to fund mine expansion and exploration

Structure weakness ‘disconnected’ from underlying data, says Jefferies

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

BioAge Labs doses first patient in QUELL-DME study

Relmada Therapeutics Says CMO-Urology Raj S. Pruthi Departs

Bristol Myers’ arlocabtagene autoleucel shows positive results in Phase 2 trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/PSIL/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PSIL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","market":"US","secType":"STK","nameCN":"AdvisorShares Psychedelics ETF","latestPrice":24.5,"timestamp":1789502400000,"preClose":25.12,"halted":0,"volume":57505,"hourTrading":{"tag":"盘后","latestPrice":25.52,"preClose":24.5,"latestTime":"19:30 EDT","volume":168,"amount":4296.44,"timestamp":1789515005327,"change":1.02,"changeRate":0.041633,"amplitude":0.041633},"delay":0,"changeRate":-0.024681528662420422,"floatShares":2319976,"shares":2319976,"eps":0,"marketStatus":"Closed","change":-0.62,"latestTime":"09-15 16:00:00 EDT","open":25.24,"high":25.3215,"low":24.14,"amount":1405286.14317,"amplitude":0.047034,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789545600000},"marketStatusCode":5,"adr":0,"exchange":"ARCA","adjPreClose":25.12,"sharesOutstanding":1184976,"nav":25.051,"aum":58118072.21,"dividendRate":0.069514,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":25.52,"preClose":24.5,"latestTime":"19:30 EDT","volume":168,"amount":4296.44,"timestamp":1789515005327,"change":1.02,"changeRate":0.041633,"amplitude":0.041633},"volumeRatio":1.273508,"impliedVol":0.4953,"impliedVolPercentile":0.8446},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","floatShares":2319976,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.273508,"shares":2319976,"dividePrice":1.7031,"high":25.3215,"amplitude":0.047034,"preClose":25.12,"low":24.14,"week52Low":15.6348,"pbRate":"--","week52High":27.0175,"institutionHeld":0,"latestPrice":24.5,"eps":0,"divideRate":0.069514,"volume":57505,"delay":0,"ttmEps":0,"open":25.24,"prevYearClose":17.17,"prevWeekClose":24.7682,"prevMonthClose":24.62,"prevQuarterClose":24.05,"fiveDayClose":24.96,"twentyDayClose":25.83,"sixtyDayClose":20.0904},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSIL\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PSIL","amount":1.68387,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2025-09-22","symbol":"PSIL","amount":0.02007,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-29","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-29"},{"date":"2025-06-23","symbol":"PSIL","amount":0.01191,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-21","symbol":"PSIL","amount":0.16343,"announcedDate":"2025-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-21","defaultRemindTime":1742563800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-21","currency":"USD","dateTimestamp":1742529600000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSIL","amount":0.05477,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-30","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSIL\",market:\"US\",,,undefined,":[{"executeDate":"2022-09-26","recordDate":"2022-09-27","paymentDate":"2022-09-30","value":0.05421,"currency":"USD"},{"executeDate":"2023-09-25","recordDate":"2023-09-26","paymentDate":"2023-09-29","value":0.00336,"currency":"USD"},{"executeDate":"2024-09-23","recordDate":"2024-09-23","paymentDate":"2024-09-30","value":0.1087,"currency":"USD"},{"executeDate":"2024-12-23","recordDate":"2024-12-23","paymentDate":"2024-12-30","value":0.05477,"currency":"USD"},{"executeDate":"2025-03-21","recordDate":"2025-03-21","paymentDate":"2025-03-28","value":0.16343,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSIL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSIL\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666514254","title":"Vanadium Resources Plans Major Share and Option Placement on ASX","url":"https://stock-news.laohu8.com/highlight/detail?id=2666514254","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666514254?lang=en_us&edition=fundamental","pubTime":"2026-09-11 08:37","pubTimestamp":1789087034,"startTime":"0","endTime":"0","summary":"Vanadium Resources Ltd. ( ($AU:VR8) ) has provided an announcement. Vanadium Resources Ltd. has announced a proposed capital raising through the is...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vanadium-resources-plans-major-share-and-option-placement-on-asx-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vanadium-resources-plans-major-share-and-option-placement-on-asx-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666659418","title":"Psychedelic: Optimi to initiate Phase 2 trial of psilocybin-assisted therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2666659418","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666659418?lang=en_us&edition=fundamental","pubTime":"2026-09-10 22:50","pubTimestamp":1789051821,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study initiation plans, a Breakth...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/psychedelic-optimi-to-initiate-phase-2-trial-of-psilocybin-assisted-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/psychedelic-optimi-to-initiate-phase-2-trial-of-psilocybin-assisted-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666910405","title":"Optimi Health to initiate Phase 2 trial of psilocybin-assisted therapy for MDD","url":"https://stock-news.laohu8.com/highlight/detail?id=2666910405","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666910405?lang=en_us&edition=fundamental","pubTime":"2026-09-10 22:25","pubTimestamp":1789050337,"startTime":"0","endTime":"0","summary":"Optimi Health (OPTH) announces plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for individuals with maj...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/optimi-health-to-initiate-phase-2-trial-of-psilocybin-assisted-therapy-for-mdd-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/optimi-health-to-initiate-phase-2-trial-of-psilocybin-assisted-therapy-for-mdd-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MEDX","OPTH","ABVC","BK4139","HYLG","NVIB","GDOC","PSIL","IDNA","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666567022","title":"Alkermes Announces Launch of 9TH Annual Alkermes Pathways Research Awards® Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2666567022","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666567022?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:00","pubTimestamp":1789038000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUA8WKBZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IBRN","ALKS","MEDX","FBT","PSIL","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666956780","title":"Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval Comp360 Provider Training","url":"https://stock-news.laohu8.com/highlight/detail?id=2666956780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666956780?lang=en_us&edition=fundamental","pubTime":"2026-09-10 18:35","pubTimestamp":1789036500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUA8YJNLY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMPS","BK4139","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666562043","title":"Compass Pathways Management Attends Investor Conference Fireside Chats in New York Week of Sept. 14","url":"https://stock-news.laohu8.com/highlight/detail?id=2666562043","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666562043?lang=en_us&edition=fundamental","pubTime":"2026-09-10 18:30","pubTimestamp":1789036255,"startTime":"0","endTime":"0","summary":"Compass Pathways management attends investor conference fireside chats in New York week of Sept. 14Compass Pathways management to join investor conferences in New York during the week of Sept. 14.Fire","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDL86MRVT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666554185","title":"Disc Medicine presents initial results from RESTORE phase 2 trial in PV patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2666554185","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666554185?lang=en_us&edition=fundamental","pubTime":"2026-09-10 08:05","pubTimestamp":1788998708,"startTime":"0","endTime":"0","summary":"Disc Medicine (IRON) “presented positive initial results from the RESTORE-PV Phase 2 trial of DISC-3405 in patients with polycythemia vera. The dat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/disc-medicine-presents-initial-results-from-restore-phase-2-trial-in-pv-patients-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/disc-medicine-presents-initial-results-from-restore-phase-2-trial-in-pv-patients-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DISC","IRON","BK4139","BBC","PSIL","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666535291","title":"U.S. Stocks on the MOVE-UGI, Chewy, Cognyte Software","url":"https://stock-news.laohu8.com/highlight/detail?id=2666535291","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666535291?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:24","pubTimestamp":1788960267,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-UGI, Chewy, Cognyte SoftwareSeptember 9 (Reuters)-The main U.S. stock indexes were on course to open lower on Wednesday, when oil prices surged past the market-sensitive $","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nL6N4510Q3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SIG","LU0080751232.USD","LU2023250504.SGD","LFST","LU0211326839.USD","LU2317271919.USD","LU2462157665.USD","IE000KEQY171.SGD","LU0174119429.USD","IE0003U64NQ7.SGD","SG9999015986.USD","LU0444973449.USD","LU0792757196.USD","LU0345774391.USD","LU1280957306.USD","LU2097829019.USD","TTAN","LU0029864427.USD","LU0345770308.USD","BK4559","SG9999014559.SGD","LU0265550946.USD","LU2357627491.SGD","FBY","LU2403377893.USD","LU2746668461.USD","METW","SG9999002224.SGD","COP","IE00BFMHRM44.USD","LU1868836757.USD","LU1301847155.USD","HK0000304797.USD","LU1917777945.USD","IE00B2Q91V27.USD","LU0368265418.SGD","LU0957808578.USD","LU0353189680.USD","LU2720916845.USD","LU0130517989.USD","LU0133085943.USD","ASO","LU1046421795.USD","LU1261432733.SGD","IE0009G5SDU7.USD","DOW","LU0957791311.USD","META","LU0096364046.USD","LU1121112475.USD","LU2272731782.SGD","LU0354030511.USD","LU0823421333.USD","CMPS","LU0345780950.USD","BK4592","LU1564329115.USD","LU1732799900.SGD","IE00B19Z3581.USD","PSIL","SG9999014906.USD","LU1868836591.USD","BK4212","BK4600","LU0211327993.USD","IE00BKVL7J92.USD","LU0943347566.SGD","IE00BJJMRX11.SGD","LU1267930573.SGD","LU0795875086.SGD","LU0256331488.USD","LU1861220207.SGD","SG9999002521.SGD","LU0127658192.USD","LU0210533765.USD","LU2129689605.HKD","METD","FMED","LU1496350171.SGD","LU1551013425.SGD","IE000BZT7R73.USD","IE00B3CCJ963.GBP","LU2404859741.USD","BK4543","LU1043141123.HKD","LU2326559502.SGD","LU1429558221.USD","LU0215105999.USD","LU0098860793.USD","LU0949170772.SGD","LU0648000940.SGD","LU0289739699.SGD","LU0054578231.USD","LU1162221912.USD","LU2237957811.SGD","BK4516","SUNB","LU1941712348.USD","LU0130103400.USD","BK4104","ERX","LU1116320901.HKD","LU0266512473.USD","LTL","LU0266013472.USD","LU1791710400.SGD","VTRS","LU0784383803.USD","IE0001KFT4U8.USD","SG9999014898.SGD","IE00BQXX3F31.USD","LU1064131342.USD","SGXZ81514606.USD","LU0820561909.HKD","LU2125154935.USD","IE00BGHQF524.EUR","LU2461242641.AUD","LU0170899867.USD","LU1935042991.SGD","IXC","LU2999663052.SGD","LU0788109394.HKD","LU0267386448.USD","LU1267930227.SGD","IE00BN29S564.USD","LU0097036916.USD","LU1069347547.HKD","LU2552382058.USD","LU0314106906.USD","IE000MB6IJN5.SGD","BK4547","IE00B5949003.HKD","LU0109392836.USD","LU1868837300.USD","XLE","LU0444971666.USD","IE00BK4W5M84.HKD","BK4539","IE00B19Z8W00.USD","IE00BKDWB100.SGD","LU1582986433.USD","LU1629891620.HKD","IE000M9KFDE8.USD","IE00BJTD4N35.SGD","BK4566","LU0068578508.USD","LU1720051108.HKD","LU2361045086.USD","XOMZ","LU2361044949.HKD","LU0052756011.USD","LU1435385759.SGD","LU1564329628.SGD","LU1201861165.SGD","LU2463028550.USD","LU2322448957.HKD","LU0784384876.USD","LU0672654240.SGD","LU0072461881.USD","LU1242518857.USD","LU1169590202.USD","LU1718418525.SGD","LU2404859667.USD","BPAY","LU1267930730.SGD","LU1894683264.USD","IE0009356076.USD","IE00B1XK9C88.USD","BK4142","SG9999015358.SGD","LU2087625088.SGD","LU0061474960.USD","LU0630314457.HKD","LU2756315318.SGD","LU1992135399.USD","IE000ITXATA3.USD","LU0528227936.USD","LU0154236417.USD","FCOM","LU1119994496.HKD","LU1642822529.SGD","IE0004445239.USD","LU0162691827.USD","LU0545039389.USD","LU1670711123.USD","LU2023250843.SGD","LU2236285917.USD","SGXZ99366536.SGD","LU0203202063.USD","LU2505996509.AUD","JILL","LU1059921491.USD","BK4094","LU2237957902.USD","XLC","IE00B19Z9505.USD","LU0784385170.HKD","LU1035773651.USD","SMETAmain","LU1430597077.USD","LU0130102774.USD","LU1670710661.SGD","LU0211326755.USD","LU0211331839.USD","METQ","LU1069344957.HKD","LU1868836914.USD","LU2129689514.USD","TRUC","LU0266512127.USD","LU0345781412.USD","LU0314104364.USD","LU1791710582.SGD","LU2458330243.SGD","BK4023","IE00BFSS7M15.SGD","LU2420271590.USD","LU2272731600.USD","LU0187121727.USD","LU1720051017.SGD","LU2471134952.CNY","LU2168564222.USD","LU2168564065.EUR","LU2168564149.EUR","SMMT","LU0225283273.USD","LU1582987324.SGD","LU2746668974.SGD","OGIG","LU0353189763.USD","LU0823434740.USD","LU1697837992.HKD","SG9999018865.SGD","LU2360107671.USD","BK4534","SG9999002232.USD","LU1929549753.HKD","LU0072462426.USD","LU1116320737.USD","LU0058720904.USD","FENY","LU0979878070.USD","LU0198837287.USD","LU0456854461.SGD","TEXU","LU1935042215.USD","WLK","LU0345770993.USD","LU2087621335.USD","LU2065171402.SGD","LU1496350502.SGD","CHYM","LU0345769631.USD","LU2054465674.USD","LU0011850046.USD","LU0106261372.USD","LU0345774631.USD","LU0276348264.USD","LU0708995401.HKD","LU2360032135.SGD","LU1699723380.USD","SOCL","XOM","BK4140","LU1674673428.USD","BK4535","LU0552385451.USD","IE00BSNM7G36.USD","LU0128525689.USD","SG9999014914.USD","LU2462611646.USD","IEO","LU0056508442.USD","XDAT","INGM","LU0784385840.USD","OXY","LU1823568750.SGD","BKNU","LU1868837136.USD","LU2592432038.USD","SFD","LU0823411888.USD","LU0868494708.USD","LU2168563687.JPY","LU0795875169.SGD","LU1804176565.USD","BK4139","LU2361044865.SGD","LU0320765646.SGD","LU2462591350.SGD","IE00B7KXQ091.USD","WEEI","LU2264538146.SGD","LU0143551892.USD","LU0203201768.USD","HK0000914686.HKD","LU1582986359.USD","LU2552382132.HKD","METV","LU0208291251.USD","LU0868494617.USD","IE00B1BXHZ80.USD","LU0203345920.USD","IE0004445015.USD","LU0477156797.USD","OILT","SGXZ51526630.SGD","LU1861558580.USD","SG9999001440.SGD","LU0823421416.USD","LU0557290698.USD","METG","IGE","LU2242650005.HKD","LU1989764664.SGD","AWAY","BK4585","LU1670627923.USD","SG9999004303.SGD","LU0234572021.USD","LU0210536198.USD","LU0320765489.SGD","LU2543165471.USD","LU2417539215.USD","LU0820561818.USD","LU1861559042.SGD","LU1153585028.USD","LU0788109477.HKD","LU0310800379.SGD","VOX","LU0477156953.USD","LU0354030438.USD","SG9999001077.SGD","IE0005OL40V9.USD","IE00B4YYXB79.USD","LU1066051498.USD","IE0000B7K699.USD","SG9999015952.SGD","LU1815333072.USD","LU0786609619.USD","BK4583","LU1914381329.SGD","LU0211328371.USD","BK4561","LU0053666078.USD","LU1894683348.USD","LU2133065610.SGD","LU0316494557.USD","LU0787776722.HKD","SG9999014575.USD","LU0689472784.USD","LU1992135472.HKD","LU2750360997.AUD","IE00BFSS8Q28.SGD","LU1506573853.SGD","SG9999018857.SGD","LU0256863811.USD","SG9999014542.SGD","LU1084165304.USD","CVX","IE00BZ1G4Q59.USD","LU2471134796.USD","LU1670628061.USD","IRT","GXPC","LU0878866978.SGD","IE00B7SZLL34.SGD","LU0300736062.USD","LU1564329032.USD","XOMX","NULC","BK4215","LU0061475181.USD","LU1582987597.SGD","LU0726765562.USD","WNDR","IE000SO60NU8.SGD","LU0553294199.USD","LU2247934214.USD","FBL","IE00B19Z3B42.SGD","LU0238689110.USD","IE00BMPRXN33.USD","IE00BMPRXQ63.HKD","BK4112","LU0889566641.SGD","LU0265550359.USD","CHWY","LU2357305700.SGD","LU2764262908.HKD","SG9999017495.SGD","LU1267930490.SGD","GAMR","LU0690374961.EUR","LU2750360641.GBP","LU1316542783.SGD","BK4524","LU2430703095.HKD","CGNT","LU0157215616.USD","LU1670711040.USD","IYE","IE00BJTD4V19.USD","IE00B4JS1V06.HKD","IE000WAW04H5.SGD","LU2602419157.SGD","LU2381873111.SGD","IE0002270589.USD","LU2764263203.CNY","DRLL","LU0882574139.USD","BK4201","GXPE","LU0256863902.USD","IE00B5TLWC47.USD","LU0149725797.USD","LU0417517546.SGD","LU1883866441.USD","LU1935043536.SGD","LU0823434583.USD","LU2430703178.SGD","LU0642271901.SGD","BKKT","GB00B4QBRK32.GBP","LU1988902786.USD","LU2065169927.USD","IE000F7OJYX1.SGD","LU0070217475.USD","LU1150488135.SGD","LU0278409577.USD","LU2265009873.SGD","LU1732800096.USD","XOMO","FXG","IE00BFXG1179.USD","LU0426417589.USD","SG9999015978.USD","LU0310799852.SGD","FCG","IE000YTNTUN2.SGD","LU1852331112.SGD","LU1267930813.SGD","LU0719512351.SGD","LU1145028129.USD","LU0496365809.HKD","LU0724617625.USD","SG9999015945.SGD","LU0308772762.SGD","LU0061474705.USD","LU0949170426.SGD","LU1430594728.SGD","GB00BDT5M118.USD","LU0310800965.SGD","PAWZ","SG9999014567.USD","LU2129689431.USD","LU0323591593.USD","METU","LU0203347892.USD","LU1941712264.USD","LU2250418816.HKD","LU0690374615.EUR","LU0079474960.USD","LU0128525929.USD","LU0096362180.USD","LU0648001328.SGD","LU1127390331.HKD","IE0034235188.USD","LU1674673691.USD","LU0082616367.USD","LU1935043023.USD","LU2272731865.HKD","SGXZ23171101.USD","LU0820562030.AUD","BK4007","LU0994945656.USD","LU1235294995.USD","LU0612318385.USD","BK4213","CI","LU0077335932.USD","LU2473716301.USD","LU2347655156.SGD","LU1032466523.USD","LU2360106780.USD","LU1242518931.SGD","LU2244417387.USD","SG9999015341.SGD","DIG","LU0683600562.USD","LU2462591277.SGD","LU1814569148.SGD","IE00BWXC8680.SGD","LU1564329461.SGD","IE00B19Z8X17.USD","LU0006306889.USD","LU2106854487.HKD","LU2322448791.USD","LU0912757837.SGD","LU1571399168.USD","BK4550","LU2102340556.USD","LU0612318971.USD","LU1035775433.USD","BK4090","LU1366333091.USD","LU0964807845.USD","LU2860962120.EUR","LU0661504455.SGD","LU2471134879.HKD","LU2498475776.HKD","IE00BQXX3D17.EUR","BK4077","LU2237438978.USD","LU0320765059.SGD","LU1066053197.SGD","IE00BJJMRY28.SGD","LU0070302665.USD","LU0109391861.USD","BK4548","GB00B4LPDJ14.GBP","LU0210528500.USD","LU0426412945.USD","LU2065170008.USD","LU0976567544.SGD","LU1935043452.HKD","TRUN","IE000W1ABFV2.USD","LU0466842654.USD","FBX","LU2063271972.USD","LU1169589451.USD","LU2347655073.USD","LU0433182093.SGD","LU2213496289.HKD","IE00BMPRXR70.SGD","LU1201861249.SGD","LU0985320562.USD","LU0980610538.SGD","TYRA","HK0000304805.HKD","LU0889565833.HKD","BK4570","BK4196","VDE","LU1815336760.USD","BK4588","BK4507","RSPC","LU1585245621.USD","BK4587","LU0345769128.USD","LU0640476718.USD","LU0654597011.USD","LU2168564495.EUR","LU1150488218.USD","LU0738911758.USD","TH","SGXZ80539844.SGD","LU2954938101.SGD","BK4197","BK4227","LU0985489474.SGD","LU1043141396.HKD","LU2505996681.GBP","LU2756315664.SGD","LU1074936037.SGD","LU1366192091.USD","LU2552382215.SGD","LU0122376428.USD","IE00BQXX3C00.GBP","IE00BK4W5L77.USD","LU1861217088.USD","LU1974910355.USD","LU0708994859.HKD","BK4581","IE0034235303.USD","LU2430703251.USD","BK4200","LU2764263039.SGD","LU1839511570.USD","LU2125154778.USD","LU1935042488.USD","UGI","LU1489326972.SGD","LU2023250330.USD","IE00B3SWFQ91.USD","IE00B775H168.HKD","SGXZ31699556.SGD","LU1551013342.USD","LU0234570918.USD","LU2487616109.SGD","SG9999014880.SGD","FTXN","LU1670710588.SGD","BK4595","LU1778281490.HKD","LU2065171311.SGD","LU1979441026.SGD","LU2896262040.SGD","EVMN","BK4122","HK0000914660.USD","LU1003077747.HKD","FBYY","LU0476273544.USD","LU1232071149.USD","LU0942090050.USD","LU2471134523.USD","LU0859254822.USD","LU2456880835.USD","LU2488822045.USD","LU2458330169.SGD","LU1548497426.USD","BKNG","LU0348723411.USD","IE00BJLML261.HKD","LU1803068979.SGD","LU0300736492.USD","LU0130518102.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666580430","title":"Compass Pathways Rises After One-Year Data for Psychedelic-Based Depression Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2666580430","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666580430?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:46","pubTimestamp":1788954365,"startTime":"0","endTime":"0","summary":"BUZZ-Compass Pathways rises after one-year data for psychedelic-based depression drug** Shares of Compass PathwaysCMPS.Orise 5.3% to $14.78 premarket** Co reports 52-week data from its late-stage trial showing that additional doses of its psychedelic-based treatment, COMP360, helped sustain reductions in depression symptoms in patients with treatment-resistant depression ** CMPS says patients who were initially assigned to the 25 mg COMP360 arm and received an additional dose in the open-label portion of the study showed an average 13-point reduction from baseline on a scale used to measure the severity of depressive episodes at week 52** Across all participants receiving a 25 mg dose during the open-label phase, response rates were 40%-45% and about 30% achieved remission during the six weeks after treatment** Compass says a rolling submission of its U.S. new drug application is underway, with final filing expected in Q4** It expects a potential commercial launch in H1 2027** As of la","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nL4N4510ZT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666584065","title":"Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 Comp005 Trial Demonstrates Additional Benefit from Another Comp360 Dose in Part C Extending Durability Out to 1 Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2666584065","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666584065?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:30","pubTimestamp":1788949800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA4GLXR1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666584051","title":"Compass Pathways - Rolling Nda Submission Underway; Final Submission on Track for Q4","url":"https://stock-news.laohu8.com/highlight/detail?id=2666584051","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666584051?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:30","pubTimestamp":1788949800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA4GLXR1:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMPS","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666584015","title":"Compass Pathways - Continue to Expect Commercial Launch in H1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2666584015","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666584015?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:30","pubTimestamp":1788949800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA4GLXR1:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMPS","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666458406","title":"Compass Pathways - Comp360 Safety Profile in Part C Consistent with Prior Parts; no New Safety Findings","url":"https://stock-news.laohu8.com/highlight/detail?id=2666458406","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666458406?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:30","pubTimestamp":1788949800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA4GLXR1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666054584","title":"Compass Pathways - 25 Mg Arm Shows Average 13-Point Madrs Reduction at Week 52 with Durability to 1 Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2666054584","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666054584?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:30","pubTimestamp":1788949800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA4GLXR1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMPS","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666303585","title":"Aureka launches placement and share purchase plan to fund mine expansion and exploration","url":"https://stock-news.laohu8.com/highlight/detail?id=2666303585","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666303585?lang=en_us&edition=fundamental","pubTime":"2026-09-09 07:53","pubTimestamp":1788911605,"startTime":"0","endTime":"0","summary":"Aureka Limited ( ($AU:AKA) ) just unveiled an update. Aureka Limited has launched a capital raising initiative comprising a $5.65 million share pla...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aureka-launches-placement-and-share-purchase-plan-to-fund-mine-expansion-and-exploration?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aureka-launches-placement-and-share-purchase-plan-to-fund-mine-expansion-and-exploration?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BK4094","BK4122","AKA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377632","title":"Structure weakness ‘disconnected’ from underlying data, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377632?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897615,"startTime":"0","endTime":"0","summary":"After Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, Jefferies see...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNCR","FHLC","IDNA","GDOC","AZNH","MEDX","SYNB","SURI","MNTL","TBXU","IEIH","BME","WDNA","GNMX","LLYX","PBE","HRTS","SBIO","NVIB","FBT","LFSC","PJP","MEDI","FTXH","MDTX","APXH","GNOM","IBRN","GSKH","BBP","XPH","PTH","RSPH","CURE","FXH","JDOC","JHMH","IBBQ","PINK","PSIL","IBBJ","IBB","MRNY","PBPH","BBH","HYLG","PSCH","BIB","CANC","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665637847","title":"Structure Therapeutics reports ACCG-2671, aleniglipron trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665637847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665637847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:36","pubTimestamp":1788871007,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNOM","MEDI","GNMX","APXH","PBPH","PBE","PSCH","WDNA","IBB","IDNA","MNTL","FBT","NVIB","GPCR","MEDX","XPH","PSIL","GSKH","FTXH","SYNB","FXH","AZNH","IBBJ","MRNY","BME","JDOC","JHMH","GDOC","MDTX","PJP","BBP","RSPH","HRTS","SURI","IBRN","HYLG","LENZ","BIB","BBH","PINK","TBXU","IBBQ","SBIO","FHLC","CURE","CANC","LLYX","CNCR","PTH","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665037847","title":"BioAge Labs doses first patient in QUELL-DME study","url":"https://stock-news.laohu8.com/highlight/detail?id=2665037847","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665037847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:35","pubTimestamp":1788870924,"startTime":"0","endTime":"0","summary":"BioAge Labs (BIOA) announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioage-labs-doses-first-patient-in-quell-dme-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioage-labs-doses-first-patient-in-quell-dme-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","PSIL","BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665676320","title":"Relmada Therapeutics Says CMO-Urology Raj S. Pruthi Departs","url":"https://stock-news.laohu8.com/highlight/detail?id=2665676320","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665676320?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:05","pubTimestamp":1788869106,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics says CMO-Urology Raj S. Pruthi departsRelmada Therapeutics’ Chief Medical Officer – Urology, Raj S. Pruthi, left the company on Sept. 3, 2026.Disclaimer:This news brief was create","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL6M2JyT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD","BK4007","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665327821","title":"Bristol Myers’ arlocabtagene autoleucel shows positive results in Phase 2 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2665327821","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665327821?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:11","pubTimestamp":1788865885,"startTime":"0","endTime":"0","summary":"Bristol Myers (BMY) announced positive Phase 2 results from the registrational QUINTESSENTIAL trial of arlocabtagene autoleucel in adult patients w...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bristol-myers-arlocabtagene-autoleucel-shows-positive-results-in-phase-2-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bristol-myers-arlocabtagene-autoleucel-shows-positive-results-in-phase-2-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1291159041.SGD","LU1883839398.USD","BMY","LU0061475181.USD","LU0237698245.USD","BK4126","LU0225284248.USD","LU1032466523.USD","LU1718418525.SGD","BK4559","BK4585","LU1093756168.USD","LU1093756325.SGD","MYE","LU0456855351.SGD","LU1989771016.USD","LU0868494617.USD","LU1670711123.USD","PSIL","LU0985481810.HKD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU1236620834.HKD","LU2133065610.SGD","LU1261432733.SGD","IE00BFTCPJ56.SGD","LU1868837300.USD","LU2596442595.SGD","BBC","LU1074936037.SGD","IE0009355771.USD","LU2360032135.SGD","FTXH","IHE","IE00BSNM7G36.USD","LU1236620750.USD","LU1430594728.SGD","LU1670710588.SGD","LU0432979614.USD","LU0882574055.USD","BK4534","LU2125154935.USD","LU0114720955.EUR","LU0267386448.USD","LU1868836914.USD","LU1670710661.SGD","LU1983299246.USD","BK4588","LU2242652126.USD","LU0321505868.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}